Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study

Article Medicine, General & Internal

Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study

Xiaoying Gu et al.

Summary: This study included 1,734 COVID-19 survivors, showing that AKI during the acute phase was associated with a higher decline in eGFR and increased risk of reduced renal function during follow-up.

EBIOMEDICINE (2022)

Add to Collection

Article Urology & Nephrology

Acute Kidney Injury Incidence, Recovery, and Long-term Kidney Outcomes Among Hospitalized Patients With COVID-19 and Influenza

Ian A. Strohbehn et al.

Summary: The incidence of AKI and mortality rates are significantly higher in patients with COVID-19 compared to influenza patients during hospitalization. However, kidney recovery among long-term survivors appears to be similar in both groups.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Urology & Nephrology

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

Shruti Gupta et al.

Summary: The study found that AKI-RRT is common among critically ill patients with COVID-19, with a mortality rate of over 50%. For patients with AKI-RRT, older age, severe oliguria, and admission to a hospital with fewer ICU beds or higher density of COVID-19 were associated with higher 28-day mortality rates.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

AKI in Hospitalized Patients with COVID-19

Lili Chan et al.

Summary: The study found that AKI is common among hospitalized COVID-19 patients in the United States, with a 46% occurrence rate and 19% of patients requiring dialysis. Independently predicting severe AKI were chronic kidney disease, male gender, and higher serum potassium levels at admission. In-hospital mortality was significantly higher in patients with AKI compared to those without AKI, with only 30% of AKI patients recovering kidney function by the time of discharge.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Summer E. Galloway et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Computer Science, Information Systems

Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data

Jeffrey G. Klann et al.

Summary: The study developed and validated an EHR-based severity phenotype for COVID-19 in hospitalized patients across 12 international sites. The comprehensive phenotype with 6 code classes showed high sensitivity for ICU admission and/or death, but individual code categories had significant variability in sensitivity.

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19

James Nugent et al.

Summary: In this retrospective cohort study, COVID-19-associated AKI was found to be associated with a greater rate of eGFR decrease after discharge compared with AKI in patients without COVID-19. This highlights the importance of monitoring kidney function and studying interventions to limit kidney disease after COVID-19-associated AKI.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Infectious Diseases

Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital

Nan-Hui Zhang et al.

Summary: The study found that over 90% of patients with new-onset kidney disease during COVID-19 hospitalization recovered from kidney disease within 4 months after discharge. Patients in the non-recovery group were older and had higher levels of discharge serum creatinine.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos et al.

Summary: Therapeutic-dose low-molecular-weight heparin reduces major thromboembolism and death in high-risk inpatients with COVID-19, with no significant effect observed in critically ill patients.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

High-dimensional characterization of post-acute sequelae of COVID-19

Ziyad Al-Aly et al.

Summary: This study comprehensively describes the post-acute sequelae of COVID-19 using national healthcare databases, finding increased risk of death and use of health resources beyond the first 30 days of illness, as well as incident sequelae in various organ systems, increased use of therapeutic agents, and evidence of laboratory abnormalities. The findings show a risk gradient according to the severity of acute COVID-19 infection and highlight the burden of health loss experienced by patients who survive the acute phase.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lopes et al.

Summary: In hospitalized COVID-19 patients with elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therapeutic-dose rivaroxaban and other direct oral anticoagulants should be avoided in these patients without an evidence-based indication for oral anticoagulation.

LANCET (2021)

Add to Collection

Review Urology & Nephrology

Pathophysiology of COVID-19-associated acute kidney injury

Matthieu Legrand et al.

Summary: Acute kidney injury (AKI) is a common complication of COVID-19, and potential mechanisms for COVID-19-associated AKI include systemic haemodynamic instability, local immune cell infiltration, and endothelial injury, which may lead to impaired kidney function.

NATURE REVIEWS NEPHROLOGY (2021)

Add to Collection

Article Critical Care Medicine

Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study

Nuttha Lumlertgul et al.

Summary: This retrospective study investigated acute kidney injury (AKI) in critically ill patients with COVID-19 in ICU, finding that AKI was highly prevalent in these patients with a portion progressing to severe stages requiring kidney replacement therapy. Steroid therapy may have a protective effect in reducing AKI progression.

ANNALS OF INTENSIVE CARE (2021)

Add to Collection

Review Peripheral Vascular Disease

Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding

Jordana B. Cohen et al.

Summary: The concerns over using ACE inhibitor or ARB for hypertension treatment during COVID-19 remain unresolved. This review discusses the sources of bias and methodologies to address them, emphasizing the importance of understanding these biases and appropriate methods for evaluating observational studies.

JOURNAL OF HYPERTENSION (2021)

Add to Collection

Article Urology & Nephrology